Abstract 61P
Background
Total neoadjuvant therapy is a combination of radiotherapy and chemotherapy for treatment of locally advanced rectal cancer, in any sequence, though RAPIDO and PRODIGE -23 have focused on this treatment protocol, in India there is no such trial done now.
Methods
Study design: Prospective interventional single-arm feasibility study. Study duration: August 2020 to May 2021. Study setting: Department of Radiotherapy in collaboration with Department of Surgical Oncology, Department of General Surgery of King George’s Medical University in Lucknow, India. Sample size 30. Sampling technique: All patients who attended radiotherapy opd during this study duration. Selection criteria: ECOG 0-1 patients with locally advanced stage I-III adenocarcinoma of middle or lower rectum. Study course: Patients received short course radiotherapy (SCRT) (25 Gray in 5 fractions over one week ) followed by six cycles of chemotherapy (Inj. oxaliplatin 130 mg / m2 on day one and Tab. capecitabine 1000 mg/m2 bid for 14 days- q3weekly). After completion of chemotherapy, all patients were sent for surgical evaluation. Objectives were to study immediate surgical outcomes in terms of pathological complete response (pCR), R0 resection rate, circumferential resection positive rate.
Results
Among the 30 recruited subjects, 6 (20%) were male and 24 (80%) were female, presentation is bleeding per rectum followed by pain and altered bowel habits. 60% were vegetarian in diet. All patients were histo-pathologically proven adenocarcinoma among 20% were signet ring types. 40% of the patients were well differentiated adenocarcinoma. 70% were T3 stage, and node positive disease. 63% of the patients had lower rectal disease. 83% had mesorectal fascia involvement. 50% had raised CEA (>5ng/ml ). 75% completed 6 cycles of chemotherapy along with 70% grade I neuropathy. 20% had grade 3 diarrhoea. 25 patients got operated. The surgical outcomes are described in the table. Table: 61P
No. of patients (n=25) | % | |
Sphincter preservation | 4 | 16.0 |
Pathological complete response | 5 | 20.0 |
Total mesorectal excision | 25 | 100.0 |
Circumferential resection margin positive | 2 | 8.0 |
R0 rate | 23 | 92.0 |
Conclusions
Intensification of this therapy has potential to increase proportion of patients who achieve complete clinical response (cCR) and could be a candidate for wait and watch.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
129P - Chemoradiation in carcinoma esophagus with weekly paclitaxel ad carboplatin: A real-world experience from a tertiary care center
Presenter: Nidhi Sharma
Session: Poster viewing 02
130P - Radiation induced lymphopenia (RAILs on time saves nine): In carcinoma esophagus
Presenter: Sheel Mohanty
Session: Poster viewing 02
131TiP - ASCEND: Randomized, double-blinded phase II study of gemcitabine and nab-paclitaxel with CEND-1 or placebo in untreated metastatic pancreatic ductal adenocarcinoma - An Australasian Gastro-Intestinal Trials Group (AGITG) trial ACTRN12621001290886
Presenter: Andrew Dean
Session: Poster viewing 02
134TiP - A phase I/II study of nanoliposomal irinotecan plus S-1 in metastatic pancreatic cancer after first-line gemcitabine-based chemotherapy
Presenter: Hiroshi Imaoka
Session: Poster viewing 02